Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
841-860 of 1,738 trials

Hepatocellular Carcinoma: Triple Treatment Study

We are studying a combination of three medications for patients with non-resectable liver cancer. The goal is to see if this approach improves symptoms and quality of life compared to past treatments.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Fibrodysplasia Ossificans Progressiva: Fidrisertib Study

We are studying a new oral medication for people with fibrodysplasia ossificans progressiva to see if it can help prevent new bone growth and improve overall health. This trial includes both children and adults to evaluate its safety and effectiveness.

Fibrodysplasia Ossificans ProgressivaEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurology

Fanconi Anemia: Afatinib for Advanced Squamous Cell Carcinoma

We are studying whether Afatinib can help patients with Fanconi anemia who have advanced squamous cell carcinoma in the head and neck. The trial will assess its effectiveness and safety compared to current treatment options.

Advanced Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Breast Cancer: Alisertib with Hormone Therapy

We are studying how well alisertib works with hormone therapy for patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. Our goal is to find the best dose and assess safety and effectiveness.

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Posaconazole for Fungal Infection Prevention in Stem Cell Transplant Patients

We are studying whether posaconazole can effectively prevent fungal infections in patients receiving stem cell transplants. This research aims to understand how well the medication works and its impact on patient recovery.

Healthy Participants>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Fanconi Anaemia: Gene Therapy Study

We are evaluating the long-term safety and effects of a gene therapy using modified cells in patients with Fanconi Anaemia Subtype A. This study aims to understand how well the treatment works and its impact on blood health over time.

Fanconi's AnemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

HIV Research: Topiramate Treatment

We are investigating whether topiramate can help activate hidden HIV in people on antiretroviral therapy. The study also examines the safety of this medication and how various factors may influence its effects.

HIV-1 Infection≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Advanced Solid Tumors: ART0380 Oral Treatment

We are studying the safety and effectiveness of the oral medication ART0380 for patients with advanced or metastatic solid tumors. This includes testing it alone and in combination with other drugs to see how well it works.

Advanced or Metastatic Solid TumoursSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: Abatacept and Daratumumab Treatment

We are studying a combination of two medications to see if it is safe and effective for people with rheumatoid arthritis who have specific antibodies. This research aims to explore new ways to manage autoimmunity in these patients.

Rheumatoid Arthritis6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Advanced Cancer: IO102-IO103 with Pembrolizumab

We are studying a new treatment combination for patients with metastatic non-small cell lung cancer, squamous cell carcinoma of the head and neck, or metastatic urothelial bladder cancer. The goal is to evaluate its effectiveness and safety as a first-line therapy.

Metastatic Squamous Cell Carcinoma of Head and NeckMetastatic Urothelial Bladder CancerMetastatic Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesOncology

Myelofibrosis: Tasquinimod Treatment Study

We are studying tasquinimod in patients with myelofibrosis who are not responding to current treatments. The goal is to see if it can safely reduce spleen size and improve symptoms.

Myelofibrosis3-6 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Alcohol-Related Liver Disease: GSK4532990 Study

We are investigating a new medication, GSK4532990, for adults with alcohol-related liver disease. The study aims to see if it is safe and effective compared to a placebo.

Alcoholic Liver Disease1-2 yearsEfficacy phase (II)11-15 visitsHepatologyInternal Medicine

Multiple Myeloma: Selinexor with Dexamethasone and Bortezomib

We are studying different combinations of Selinexor, Dexamethasone, and Bortezomib for patients with hard-to-treat multiple myeloma. Our goal is to see how well these treatments work and how safe they are.

Multiple MyelomaRelapsed/Refractory Multiple MyelomaPenta-Refractory Multiple Myeloma3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Locally-Advanced Rectal Cancer: Tailored Treatment Study

We are studying a personalized treatment plan for patients with locally-advanced rectal cancer who respond well to initial chemotherapy. The goal is to see if this approach maintains effective surgery outcomes while reducing treatment intensity.

Rectal Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Sodium Thiosulfate Injections for Ectopic Calcifications

We are studying whether injections of sodium thiosulfate can help reduce calcifications and ossifications in patients with certain autoimmune conditions. This trial will also look at the treatment's safety and its impact on pain and quality of life.

Ectopic Calcification and Ossification>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Esophageal Adenocarcinoma: Metformin Treatment

We are studying whether metformin can enhance the immune response in patients with esophageal adenocarcinoma receiving chemoradiotherapy. This research may help improve treatment effectiveness and patient outcomes.

Oesophageal Adenocarcinoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Daratumumab for Very High-Risk T-Cell Acute Lymphoblastic Leukemia

We are studying whether adding daratumumab to standard treatment helps adults with very high-risk T-ALL achieve better disease control. This trial will also assess the safety and effectiveness of this combination therapy.

Very High-Risk T-Lineage Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Hodgkin's Lymphoma: Atezolizumab and BEGEV Treatment

We are studying a new combination treatment for patients with relapsed or refractory Hodgkin's lymphoma to see if it helps improve response rates before stem-cell transplantation. This trial will also evaluate the safety and tolerability of this treatment approach.

Hodgkin's Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Mantle Cell Lymphoma: Loncastuximab Tesirine Treatment

We are studying whether loncastuximab tesirine can improve outcomes for patients with relapsed or refractory mantle cell lymphoma after immunochemotherapy. The trial also looks at the safety of this treatment and its effectiveness in reducing disease presence.

Mantle Cell LymphomaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Plasmablastic Lymphoma: Daratumumab with Bortezomib and Dexamethasone

We are studying a combination of daratumumab, bortezomib, and dexamethasone for patients with relapsed or refractory plasmablastic lymphoma. The goal is to see if this treatment improves outcomes for those who cannot undergo stem cell transplantation.

Relapsed or Refractory Plasmablastic Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology